| | | | | 1 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 8 | | | |
| | | | | 23 | | | |
| | | | | 25 | | | |
| | | | | 31 | | | |
| | | | | 32 | | | |
| | | | | 33 | | | |
| | | | | 33 | | | |
| | | | | 35 | | | |
| | | | | 35 | | | |
| | | | | 36 | | | |
| | | | | 37 | | | |
| | | | | 38 | | | |
| | | | | 38 | | | |
| | | | | 38 | | |
|
Date:
|
| | June 14, 2022 | |
|
Time:
|
| | 8:00 a.m. Eastern Time | |
|
Location:
|
| | The meeting can be accessed by visiting https://web.lumiagm.com/236626312, where you will be able to attend the meeting live via webcast, submit questions and vote online. There will be no physical location for stockholders to attend. | |
|
Record Date:
|
| | April 18, 2022 | |
|
Number of Common Shares Eligible to Vote as of the Record Date:
|
| | 43,621,453 | |
| | | | | | |
Board Recommendation
|
| |
Page Reference
(for more detail) |
|
|
Proposal 1:
|
| | Elect Seven Directors | | |
☒
FOR EACH NOMINEE
|
| |
30
|
|
|
Proposal 2:
|
| | Ratify the appointment of KPMG LLP as Independent Registered Public Accounting Firm for the 2022 Fiscal Year | | |
☒
FOR
|
| |
31
|
|
|
Proposal 3:
|
| | Approve, on an advisory basis, the compensation of our named executive officers | | |
☒
FOR
|
| |
32
|
|
| | | | | | | | | | | |
Committee Membership
|
| ||||||
Name
|
| |
Age
|
| |
Director
Since |
| |
Principal Occupation
|
| |
AC
|
| |
CC
|
| |
NCGC
|
|
Armando Anido | | |
64
|
| |
2014
|
| | Chairman & Chief Executive Officer of Zynerba Pharmaceuticals, Inc. | | | | | | | | | | |
John Butler
|
| |
57
|
| |
2018
|
| |
President and Chief Executive Officer of Akebia Therapeutics, Inc.
|
| | | | |
|
| |
|
|
Warren D. Cooper, MB, BS, BSc, MFPM†
|
| |
69
|
| |
2015
|
| |
Partner & Chief Medical Officer of Healthcare Royalty Partners
|
| |
|
| | | | |
|
|
William J. Federici
|
| |
62
|
| |
2015
|
| |
Retired Senior Vice President and Chief Financial Officer of West Pharmaceutical Services, Inc.
|
| |
|
| | | | | | |
Daniel L. Kisner, MD
|
| |
75
|
| |
2015
|
| |
Independent Consultant
|
| | | | |
|
| | | |
Kenneth I. Moch
|
| |
67
|
| |
2015
|
| |
Independent Consultant
|
| |
|
| |
|
| | | |
Pamela Stephenson
|
| |
54
|
| |
2019
|
| |
Chief Commercial Officer of Albireo Pharma, Inc.
|
| | | | | | | |
|
|
| Size of Board (set by the Board) | | | 7 | |
| Number of Independent Directors | | | 6 | |
| Lead Independent Director | | | Yes | |
| Board Self-Evaluation | | | Annual | |
| Review of Independence of Board | | | Annual | |
| Independent Directors Meet Without Management Present | | | Yes | |
| Annual Director Elections | | | Yes | |
| Voting Standard for Election of Directors | | | Plurality | |
| Diversity of Board background, experience and skills | | | Yes | |
Proposal
|
| |
Votes Required
|
| |
Treatment of Abstentions and
Broker Non-Votes |
| |
Broker
Discretionary Voting |
|
Proposal 1 – Election of Seven Directors | | | Plurality of votes cast | | | Abstentions and broker non-votes will not be taken into account in determining the outcome of the proposal | | |
No
|
|
Proposal 2 – Ratification of Appointment of KPMG LLP as our Independent Registered Public Accounting Firm for the 2022 Fiscal Year | | | Majority of shares present and entitled to vote on the proposal in person (virtually) or represented by proxy | | | Abstentions and broker non-votes will have the effect of negative votes. | | |
Yes
|
|
Proposal 3 – To approve, on an advisory basis, the compensation of our named executive officers. | | | Majority of shares present and entitled to vote on the proposal in person (virtually) or represented by proxy | | | Abstentions and votes withheld will have the same effect as a negative vote. Broker non-votes will not be taken into account in determining the outcome of the proposal. | | |
No
|
|
|
|
| |
|
| |
|
|
|
Mailing your signed proxy card or voter instruction card.
|
| |
Using the Internet at www.voteproxy.com.
|
| |
Calling toll-free from the United States, U.S. territories and Canada to 1-800-776-9437.
|
|
| | | | | | | | |
Committee Membership
|
| ||||||
Name, Age
|
| |
Age
|
| |
Position
|
| |
AC
|
| |
CC
|
| |
NCGC
|
|
Armando Anido | | |
64
|
| | Chairman of the Board and CEO | | | | | | | | | | |
Terri B. Sebree | | |
64
|
| | President | | | | | | | | | | |
James E. Fickenscher | | |
58
|
| | CFO and VP, Corporate Development | | | | | | | | | | |
Albert P. Parker | | |
56
|
| | Chief Legal Officer and Corporate Secretary | | | | | | | | | | |
Brian Rosenberger | | |
53
|
| | VP, Commercial and Business Development | | | | | | | | | | |
John P. Butler
|
| |
57
|
| |
Director
|
| | | | |
|
| |
|
|
Warren D. Cooper, MB, BS, BSc, MFPM†
|
| |
69
|
| |
Director
|
| |
|
| | | | |
|
|
William J. Federici
|
| |
62
|
| |
Director
|
| |
|
| | | | | | |
Daniel L. Kisner, MD
|
| |
75
|
| |
Director
|
| | | | |
|
| | | |
Kenneth I. Moch
|
| |
67
|
| |
Director
|
| |
|
| |
|
| | | |
Pamela Stephenson
|
| |
54
|
| |
Director
|
| | | | | | | |
|
|
| Terri B. Sebree | | ||||||
|
Age: 64
President Officer Since: 2014 |
| | | | |
Other Public Directorships: None
|
|
| Terri B. Sebree has served as our president since October 2014, and served as our treasurer from October 2014 to December 2014. Prior to joining our company, Ms. Sebree served as our business consultant from May 2014 to October 2014. Ms. Sebree has more than 35 years of executive, development and operational experience in the pharmaceutical industry, particularly in central nervous system product development including epilepsy and pain. Ms. Sebree founded and served as president of NuPathe, a specialty pharmaceutical company, from February 2005 until April 2014, where she led the effort to develop, achieve regulatory approval for and complete manufacturing of the company’s lead product, Zecuity, a transdermal patch for migraines. Prior to founding NuPathe, Ms. Sebree served as senior vice president, development of Auxilium, a specialty pharmaceutical company, where she led the development and approval program of Testim, a testosterone gel. Prior to joining Auxilium, Ms. Sebree served as executive vice president, U.S. Operations at IBAH, Inc., a contract research organization. Prior to that, Ms. Sebree served in a variety of management roles with Abbott Laboratories Inc., a global healthcare company, for over nine years. Ms. Sebree currently serves on the board of directors of Serodus ASA, a private Scandinavian pharmaceutical company. Ms. Sebree holds a B.S. from Texas A&M University. | |
| James E. Fickenscher | | ||||||
|
Age: 58
CFO and VP, Corporate Development Officer Since: 2016 |
| | | | |
Other Public Directorships: None
|
|
| James E. Fickenscher has served as our chief financial officer, vice president corporate development since September 2016. Mr. Fickenscher has more than 30 years of financial, business development and executive leadership experience in the pharmaceutical industry. Prior to joining our company, he served as the senior vice president, chief financial officer of Antares Pharma, Inc., a specialty pharmaceutical company, from November 2014 to September 2016. Previously, Mr. Fickenscher served as chief financial officer of Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, from May 2005 until August 2014. From January 2000 until April 2004, Mr. Fickenscher served as senior vice president chief financial officer of Aventis Behring L.L.C., a wholly owned subsidiary of Aventis, predecessor to Sanofi S.A. Mr. Fickenscher joined Aventis Behring L.L.C. in 1995 as vice president, business development and strategic planning and, from that time until 2000, also held the positions of general manager, Japan and vice president & general manager, Hemophilia Business Unit. Throughout his tenure at Aventis Behring L.L.C, he was also responsible for strategic planning. Prior to Aventis Behring L.L.C., Mr. Fickenscher worked at Rhone-Poulenc Rorer, predecessor to Sanofi S.A., in its Collegeville, PA and Paris, France offices and at Deloitte & Touche LLP. Mr. Fickenscher received his B.S. at Bloomsburg University of Pennsylvania. He is a member of the American Institute of Certified Public Accountants. | |
| Albert P. Parker | | ||||||
|
Age: 56
Chief Legal Officer and Corporate Secretary Officer Since: 2022 |
| | | | |
Other Public Directorships: None
|
|
| Albert P. Parker has served as our Chief Legal Officer since February 2022. Mr. Parker is an accomplished business and legal executive with more than 25 years of experience in highly regulated industries, including pharmaceuticals, biotech, and medical diagnostics. He has developed deep operating and legal expertise in various C-suite roles for publicly traded healthcare companies and has a proven track record of successfully managing corporate operations and leading legal and compliance teams on a global scale. Prior to Zynerba, Mr. Parker served as Chief Operating Officer and Corporate Secretary for Oncocyte Corporation, a Nasdaq-listed molecular diagnostics company where he led significant M&A and other transactions and had overall P&L responsibility for corporate and lab operations and G&A departments including Legal, HR, IT, and Facilities. Additional roles over the course of his career include Executive VP, General Counsel and Corporate Secretary for Sunovion, a multinational pharma company, and Senior VP & Global Chief Counsel for Wyeth, a Fortune 100 biopharmaceutical company. A former partner at an AmLaw 250 law firm and founder of a healthcare boutique, Mr. Parker received his J.D. from the University of Pennsylvania Law School, and his B.A. in Economics from Penn State University. | |
| Brian Rosenberger | | ||||||
|
Age: 53
VP, Commercial and Business Development Officer Since: 2017 |
| | | | |
Other Public Directorships: None
|
|
| Brian Rosenberger has served as our vice president, commercial and business development, since January 2017. Over his career in the pharmaceutical industry, Mr. Rosenberger has held several leadership roles in marketing, sales, business development analytics and alliance management. Prior to joining our company, he was vice president, alliance & strategic portfolio management at Cipher Pharmaceuticals, a publicly-traded, Canadian-based dermatology company, from May 2015 to January 2017, where he managed the company’s global portfolio. From 2008 to April 2015, Mr. Rosenberger also held various roles of increasing responsibility at Auxilium Pharmaceuticals, a specialty biopharmaceutical company. In his last role as executive director, corporate development & licensing and alliance management he participated in several transformational M&A, licensing and co-promotion deals through and including Endo International’s acquisition of Auxilium in January 2015. Prior to joining Auxilium, Mr. Rosenberger held sales managerial positions at Neurocrine Biosciences during the initial commercial build-out of the organization and spent over a decade at GlaxoSmithKline in various U.S. and global commercial roles within specialty markets. Mr. Rosenberger received a B.A. double major in Political Science/Policy and Management Studies from Dickinson College in Carlisle, PA. | |
| Warren D. Cooper, MB, BS, BSc, MFPM | | ||||||
|
Age: 69
Board Member Since: 2015 |
| | Committee Memberships: Audit Committee, Member; Nominating and Corporate Governance Committee, Member | | |
Other Public Directorships: None
|
|
| Warren D. Cooper, MB, BS, BSc, MFPM has served as a member of our Board since August 2015. Dr. Cooper is a U.K.-trained physician with more than 40 years of experience in the global pharmaceutical industry. Since January 2017, Dr. Cooper has served as chief medical officer and a partner of Healthcare Royalty Partners, a healthcare investment firm. Prior to joining Healthcare Royalty Partners in January 2017, Dr. Cooper served as the president of Coalescence Inc., a healthcare and pharmaceutical development consultancy, where he held various positions since 1999. Dr. Cooper was the chief executive officer of Prism Pharmaceuticals, Inc., a venture-backed, specialty pharmaceutical company that he led from inception in September 2004 until the sale of the company to Baxter International in May 2011. His career in the pharmaceutical industry began with Merck, Sharp and Dohme and spanned 12 years, initially as a clinical research physician in the United Kingdom, then as head of European and, subsequently, Worldwide Clinical Research Operations for Merck Research Laboratories across all therapeutic areas. Moving to AstraMerck (now AstraZeneca PLC, or “AstraZeneca”), in a broad clinical development role, he eventually led that company’s cardiovascular business division, a role with full business lifecycle leadership from in-licensing through development, to P&L responsibility for sales and marketing. Dr. Cooper is a member of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom. He has previously served on the boards of directors of Nutrition 21, Inc., Nuron Biotech Inc., Cardiorentis AG and the World Affairs Council of Philadelphia. Dr. Cooper holds a B.Sc. in Physiology, an M.B. and a B.S., each from the London Hospital, University of London. | | ||||||
| Skills and Qualifications: With more than 40 years of experience in the global pharmaceutical industry, Dr. Cooper brings valuable expertise in pharmaceutical company leadership and clinical pharmaceutical research to our Board. | |
| Pamela Stephenson | | ||||||
|
Age: 54
Board Member Since: 2019 |
| | Committee Memberships: Nominating and Corporate Governance Committee, Chair | | |
Other Public Directorships: None
|
|
| Pamela Stephenson was appointed as a member of our Board of Directors in February 2019. Ms. Stephenson has more than 20 years of experience leading the development and implementation of pharmaceutical marketing plans. Since March 2019, Ms. Stephenson has served as chief commercial officer for Albireo Pharma, Inc., a publicly traded biopharmaceutical company. Prior to that, she served as a vice president at Vertex Pharmaceuticals, Inc. (“Vertex”), a publicly traded global biotechnology company, from July 2008 to March 2019, where she was responsible for leading the global market access and pricing strategy for current and future products. Earlier in her tenure at Vertex, Ms. Stephenson led marketing and sales activities for the company’s hepatitis C and cystic fibrosis lines of business, and oversaw the U.S. launches of Incivek® (telaprevir) and Orkambi® (lumacaftor/ivacaftor). Prior to Vertex, Ms. Stephenson held roles of increasing strategic importance at Pfizer Inc., a publicly traded global pharmaceutical company, from October 1998 to June 2008. Ms. Stephenson received her B.A. from Brown University and M.P.H. from the Boston University School of Public Health. | | ||||||
| Skills and Qualifications: With her extensive experience in the commercialization and marketing of pharmaceutical products, including for the treatment of rare and near rare diseases, Ms. Stephenson brings valuable expertise in commercial planning, market development, product launch and market access to our Board. | |
|
Director Skills and Experience
|
| ||||||||||||||||||||||||||||||||||||||||||
| | | |
Anido
|
| |
Butler
|
| |
Cooper
|
| |
Federici
|
| |
Kisner
|
| |
Moch
|
| |
Stephenson
|
| |||||||||||||||||||||
|
Pharmaceutical Industry
|
| | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| |
|
Executive Leadership
|
| | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| |
|
Finance & Accounting
|
| | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| |
|
Corporate Governance
|
| | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| |
|
Executive Compensation
|
| | |
|
✓
|
| | | |
|
✓
|
| | | | | | | | | | | | | | | |
|
✓
|
| | | |
|
✓
|
| | | | | | | |
|
Regulatory Risk Management
|
| | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| |
|
Commercialization/Sales & Marketing
|
| | |
|
✓
|
| | | |
|
✓
|
| | | | | | | | | | | | | | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| |
|
Corporate Strategy & Business Development
|
| | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| |
|
Partnering/Mergers & Acquisitions
|
| | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| |
Name of Non-Employee Director
|
| |
Fee Earned or
Paid in Cash ($) |
| |
Stock
Awards ($)(1) |
| |
Option
Awards ($)(2) |
| |
Total ($)
|
| ||||||||||||
Warren D. Cooper, MB, BS, BSc, MFPM(3)
|
| | | | 80,000 | | | | | | 22,200 | | | | | | 24,664 | | | | | | 126,864 | | |
John P. Butler(3)
|
| | | | 52,000 | | | | | | 22,200 | | | | | | 24,664 | | | | | | 98,864 | | |
William J. Federici(3)
|
| | | | 60,000 | | | | | | 22,200 | | | | | | 24,664 | | | | | | 106,864 | | |
Daniel L. Kisner, M.D.(3)
|
| | | | 55,000 | | | | | | 22,200 | | | | | | 24,664 | | | | | | 101,864 | | |
Kenneth I. Moch(3)
|
| | | | 57,000 | | | | | | 22,200 | | | | | | 24,664 | | | | | | 103,864 | | |
Pamela Stephenson(3)
|
| | | | 50,000 | | | | | | 22,200 | | | | | | 24,664 | | | | | | 96,864 | | |
Position
|
| |
Additional Cash
Retainer in 2021 ($) |
| |
Additional Cash
Retainer in 2022 ($) |
| ||||||
Audit Committee | | | | | | | | | | | | | |
Chair
|
| | | | 20,000 | | | | | | 20,000 | | |
Member
|
| | | | 10,000 | | | | | | 10.000 | | |
Compensation Committee | | | | | | | | | | | | | |
Chair
|
| | | | 15,000 | | | | | | 15,000 | | |
Member
|
| | | | 7,000 | | | | | | 7,500 | | |
Nominating and Corporate Governance Committee | | | | | | | | | | | | | |
Chair
|
| | | | 10,000 | | | | | | 10.000 | | |
Member
|
| | | | 5,000 | | | | | | 5,000 | | |
Name and Principal Position
|
| |
Year
|
| |
Salary ($)
|
| |
Non-equity
incentive plan compensation ($)(1) |
| |
Stock
Awards ($)(2) |
| |
Option
Awards ($)(3) |
| |
All Other
Compensation ($)(4) |
| |
Total ($)
|
| |||||||||||||||||||||
Armando Anido
|
| | | | 2021 | | | | | | 603,000 | | | | | | 379,675 | | | | | | 772,643 | | | | | | 446,472 | | | | | | 10,685 | | | | | | 2,212,475 | | |
Chairman of the Board and CEO
|
| | | | 2020 | | | | | | 585,265 | | | | | | 263,369 | | | | | | — | | | | | | 580,674 | | | | | | 10,542 | | | | | | 1,439,850 | | |
Terri B. Sebree
|
| | | | 2021 | | | | | | 464,409 | | | | | | 288,933 | | | | | | 537,000 | | | | | | 303,409 | | | | | | 10,685 | | | | | | 1,604,436 | | |
President
|
| | | | 2020 | | | | | | 450,883 | | | | | | 209,660 | | | | | | — | | | | | | 428,858 | | | | | | 10,542 | | | | | | 1,099,943 | | |
James E. Fickenscher
|
| | | | 2021 | | | | | | 422,230 | | | | | | 175,127 | | | | | | 372,320 | | | | | | 215,145 | | | | | | 10,663 | | | | | | 1,195,485 | | |
CFO and VP, Corporate Development
|
| | | | 2020 | | | | | | 409,932 | | | | | | 129,129 | | | | | | — | | | | | | 303,775 | | | | | | 10,520 | | | | | | 853,356 | | |
| Abeona Therapeutics | | | Chiasma, Inc. | | | Ocular Therapeutics, Inc. | |
| Adamas Pharmaceuticals, Inc. | | | Concert Pharmaceuticals, Inc. | | | Otonomy, Inc. | |
| Alimera Sciences, Inc | | | Corbus Pharmaceuticals, Inc. | | | Ovid Therapeutics Inc. | |
| Ardelyx, Inc | | | Cymabay Therapeutics | | | Rigel Pharmaceuticals | |
| Assembly Biosciences, Inc | | | Five Prime Therapeutics | | | Seres Therapeutics, Inc. | |
| Athersys, Inc. | | | Geron Corp. | | | Syros Pharmaceuticals, Inc. | |
| Biocryst Pharmaceuticals, Inc. | | | Glycomimetics, Inc. | | | Trevena | |
| Calithera Biosciences | | | Marinus Pharmaceuticals | | | Ziopharm Oncology, Inc. | |
| Cara Therapeutics, Inc. | | | Medicinova Inc. | | | | |
| Catabasis Pharmaceuticals, Inc. | | | Minerva Neurosciences, Inc. | | | | |
| Abeona Therapeutics | | | Concert Pharmaceuticals, Inc. | | | Minerva Neurosciences, Inc. | |
| Acelrx Pharmaceutical | | | Corbus Pharmaceuticals, Inc. | | | Ocular Therapeutics, Inc. | |
| Ardelyx, Inc | | | Cymabay Therapeutics | | | Otonomy, Inc. | |
| Assembly Biosciences, Inc | | | Geron Corp. | | | Ovid Therapeutics Inc. | |
| Athersys, Inc. | | | Glycomimetics, Inc. | | | Relmada Therapeutic | |
| Calithera Biosciences | | | Lipocine Inc. | | | Syros Pharmaceuticals, Inc. | |
| Cara Therapeutics, Inc. | | | Marinus Pharmaceuticals, Inc. | | | Ziopharm Oncology, Inc. | |
| Catabasis Pharmaceuticals, Inc. | | | Medicinova | | | | |
| | | | | | | | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||
Name
|
| |
Grant Date
|
| |
Number of
Securities Underlying Unexercised Options (#) (Exercisable) |
| |
Number of
Securities Underlying Unexercised Options (#) (Unexercisable)(1) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares or Units of Stock That Have Not Vested (#) |
| |
Market
Value of Shares or Units of Stock That Have Not Vested ($)(2) |
| |||||||||||||||||||||
Armando Anido
|
| | | | 10/02/2014 | | | | | | 292,553 | | | | | | — | | | | | | 3.98 | | | | | | 10/02/2024 | | | | | | — | | | | | | — | | |
| | | | | 08/04/2015 | | | | | | 396,678 | | | | | | — | | | | | | 14.00 | | | | | | 08/04/2025 | | | | | | — | | | | | | — | | |
| | | | | 01/25/2017 | | | | | | 125,000 | | | | | | — | | | | | | 18.22 | | | | | | 01/25/2027 | | | | | | — | | | | | | — | | |
| | | | | 01/11/2018 | | | | | | 75,938 | | | | | | 5,062 | | | | | | 11.71 | | | | | | 01/11/2028 | | | | | | — | | | | | | — | | |
| | | | | 01/24/2019 | | | | | | 110,000 | | | | | | 50,000 | | | | | | 3.65 | | | | | | 01/24/2029 | | | | | | — | | | | | | — | | |
| | | | | 01/30/2020 | | | | | | 71,085 | | | | | | 91,395 | | | | | | 5.05 | | | | | | 01/30/2030 | | | | | | — | | | | | | — | | |
| | | | | 01/21/2021 | | | | | | — | | | | | | 161,867 | | | | | | 3.58 | | | | | | 01/21/2031 | | | | | | — | | | | | | — | | |
| | | | | 01/21/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 107,911(3) | | | | | | 310,784 | | |
| | | | | 01/21/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 107,911(4) | | | | | | 310,784 | | |
Terri B. Sebree
|
| | | | 10/02/2014 | | | | | | 146,276 | | | | | | — | | | | | | 3.98 | | | | | | 10/02/2024 | | | | | | — | | | | | | — | | |
| | | | | 08/04/2015 | | | | | | 201,981 | | | | | | — | | | | | | 14.00 | | | | | | 08/04/2025 | | | | | | — | | | | | | — | | |
| | | | | 01/25/2017 | | | | | | 75,000 | | | | | | — | | | | | | 18.22 | | | | | | 01/25/2027 | | | | | | — | | | | | | — | | |
| | | | | 01/11/2018 | | | | | | 41,175 | | | | | | 2,745 | | | | | | 11.71 | | | | | | 01/11/2028 | | | | | | — | | | | | | — | | |
| | | | | 01/24/2019 | | | | | | 82,500 | | | | | | 37,500 | | | | | | 3.65 | | | | | | 01/24/2029 | | | | | | — | | | | | | — | | |
| | | | | 01/30/2020 | | | | | | 52,500 | | | | | | 67,500 | | | | | | 5.05 | | | | | | 01/30/2030 | | | | | | — | | | | | | — | | |
| | | | | 01/21/2021 | | | | | | — | | | | | | 110,000 | | | | | | 3.58 | | | | | | 01/21/2031 | | | | | | — | | | | | | — | | |
| | | | | 01/21/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 75,000(3) | | | | | | 216,000 | | |
| | | | | 01/21/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 75,000(4) | | | | | | 216,000 | | |
James E. Fickenscher
|
| | | | 09/13/2016 | | | | | | 150,000 | | | | | | — | | | | | | 10.23 | | | | | | 09/13/2026 | | | | | | — | | | | | | — | | |
| | | | | 01/25/2017 | | | | | | 31,350 | | | | | | — | | | | | | 18.22 | | | | | | 01/25/2027 | | | | | | — | | | | | | — | | |
| | | | | 01/11/2018 | | | | | | 63,281 | | | | | | 4,219 | | | | | | 11.71 | | | | | | 01/11/2028 | | | | | | — | | | | | | — | | |
| | | | | 01/24/2019 | | | | | | 60,568 | | | | | | 27,531 | | | | | | 3.65 | | | | | | 01/24/2029 | | | | | | — | | | | | | — | | |
| | | | | 01/30/2020 | | | | | | 37,188 | | | | | | 47,812 | | | | | | 5.05 | | | | | | 01/30/2030 | | | | | | — | | | | | | — | | |
| | | | | 01/21/2021 | | | | | | — | | | | | | 78,000 | | | | | | 3.58 | | | | | | 01/21/2031 | | | | | | — | | | | | | — | | |
| | | | | 01/21/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 52,000(3) | | | | | | 149,760 | | |
| | | | | 01/21/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 52,000(4) | | | | | | 149,760 | | |
Name of Beneficial Owner
|
| |
Amount and
Nature of Beneficial Ownership(1) |
| |
Percent of
Class |
| ||||||
Directors and Executive Officers: | | | | | | | | | | | | | |
Armando Anido(2)
|
| | | | 2,015,435 | | | | | | 4.51% | | |
Terri B. Sebree(3)
|
| | | | 1,172,698 | | | | | | 2.65% | | |
James E. Fickenscher(4)
|
| | | | 687,336 | | | | | | 1.57% | | |
John P. Butler(5)
|
| | | | 90,000 | | | | | | * | | |
Warren D. Cooper, MB, BS, BSc, MFPM(6)
|
| | | | 115,000 | | | | | | * | | |
William J. Federici(7)
|
| | | | 122,865 | | | | | | * | | |
Daniel L. Kisner, MD(8)
|
| | | | 115,000 | | | | | | * | | |
Kenneth I. Moch(9)
|
| | | | 127,055 | | | | | | * | | |
Pamela Stephenson(10)
|
| | | | 70,000 | | | | | | * | | |
All directors, director nominees and executive officers as a group (11 persons)(11)
|
| | | | 4,902,435 | | | | | | 10.54% | | |
5% or more Stockholders | | | | | | | | | | | | | |
ETF Managers Group LLC(12)
|
| | | | 3,526,304 | | | | | | 8.11% | | |
| | |
2021
|
| |
2020
|
| ||||||
Audit Fees
|
| | | $ | 386,250 | | | | | $ | 403,500 | | |
Audit-related Fees
|
| | | | — | | | | | | — | | |
Tax Fees
|
| | | | — | | | | | | — | | |
All Other Fees
|
| | | | 1,780 | | | | | | 1,780 | | |
Total
|
| | | $ | 388,030 | | | | | $ | 405,280 | | |